Honeybee Venom Immunotherapy: Certainties and pitfalls

• Bilò BM , RuëffF, MosbechH, BonifaziF, Oude Elberink JNG. The EAACI Interest Group on insect venom hypersensitivity: diagnosis of hymenoptera venom allergy. Allergy60 , 1339–1349 (2005).
   PubMed Web of Science ®Google Scholar
• Bilò MB , BonifaziF. The natural history and epidemiology of insect venom allergy: clinical implications. Clin. Exp. Allergy39 , 1467–1476 (2009).
   PubMed Web of Science ®Google Scholar
• Brown TC , TankersleyMS. The sting of the honeybee: an allergic perspective. Ann. Allergy Asthma Immunol.107 , 463–470 (2011).
   PubMed Web of Science ®Google Scholar
• Novembre E , CianferoniA, BernardiniR et al. Epidemiology of insect venom sensitivity in children and its correlation to clinical and atopic features. Clin. Exp. Allergy 28 , 834–838 (1998).
   PubMed Web of Science ®Google Scholar
• Marques L , VegaA, MunozE, Moreno-AncilloA. Epidemiologic observations on Hymenoptera allergy in Spain: the alergologica-2005 study. J. Investig. Allergol. Clin. Immunol.19 , 51–55 (2009).
   PubMed Web of Science ®Google Scholar
• Prado M , QuirosD, LomonteB. Mortality due to Hymenoptera stings in Costa Rica, 1985–2006. Pan Am. J. Public Health25 , 389–393 (2009).
   Web of Science ®Google Scholar
• Müller U . Bee venom allergy in beekeepers and their family members. Curr. Opin Allergy Clin. Immunol.5 , 343–347 (2005).
   PubMed Web of Science ®Google Scholar
• Celikel S , KarakayaG, YurtseverN, SorkunK, KalyoncuAF. Bee and bee products allergy in Turkish beekeepers: determination of risk factors for systemic reactions. Allergol. Immunopathol. (Madr.).180–184 (2006).
   PubMed Web of Science ®Google Scholar
• Richter AG , NightingaleP, HuissoonAP, KrishnaMT. Risk factors for systemic reactions to bee venom in British beekeepers. Ann. Allergy Asthma Immunol.106 , 159–163 (2011).
   PubMed Web of Science ®Google Scholar
• Eich-Wanger C , MüllerUR. Bee sting allergy in beekeepers. Clin. Exp. Allergy.28 , 1292–1298 (1998).
   PubMed Web of Science ®Google Scholar
• Müller UR . Hymenoptera venom proteins and peptides for diagnosis and treatment of venom allergic patients. Inflamm. Allergy Drug Targets10 , 420–428 (2011).
   PubMedGoogle Scholar
• Francese S , LambardiD, MastrobuoniG, la Marca G, Moneti G, Turillazzi S. Detection of honeybee venom in envenomated tissues by direct MALDI MSI. J. Am. Soc. Mass. Spectrom.20 , 112–123 (2009).
   PubMed Web of Science ®Google Scholar
• Mustafa FB , NgFS, NguyenTH, LimLH. Honeybee venom secretory phospholipase A2 induces leukotriene production but not histamine release from human basophils. Clin. Exp. Immunol.151 , 94–100 (2008).
   PubMed Web of Science ®Google Scholar
• Marković-Housley Z , MiglieriniG, SoldatovaL, RizkallahPJ, MüllerU, SchirmerT. Crystal structure of hyaluronidase, a major allergen of bee venom. Structure15(8) , 1025–1035 (2000).
   Google Scholar
• Jin C , FockeM, LéonardR, JarischR, AltmannF, HemmerW. Reassessing the role of hyaluronidase in yellow jacket venom allergy. J. Allergy Clin. Immunol.125 , 184–190 (2010).
   PubMed Web of Science ®Google Scholar
• Grunwald T , BockischB, SpillnerE, RingJ, BredehorstR, OllertMW. Molecular cloning and expression in insect cells of honeybee venom allergen acid phosphatase (Api m 3). J. Allergy Clin. Immunol.117 , 848–854 (2006).
   PubMed Web of Science ®Google Scholar
• Seppälä U , FranceseS, TurillazziS, MonetiG, ClenchM, BarberD. In situ imaging of honeybee (Apis mellifera) venom components from aqueous and aluminum hydroxide-adsorbed venom immunotherapy preparations. J. Allergy Clin. Immunol.129 , 1314–1320 (2012).
   PubMed Web of Science ®Google Scholar
• Winningham KM , FitchCD, SchmidtM, HoffmanDR. Hymenoptera venom protease allergens. J. Allergy Clin. Immunol.114 , 928–933 (2004).
   PubMed Web of Science ®Google Scholar
• Blank S , SeismannH, BockischB et al. Identification, recombinant expression, and characterization of the 100 kDa high molecular weight Hymenoptera venom allergens Api m 5 and Ves v 3. J. Immunol. 1(184) , 5403–5413 (2010).
   Google Scholar
• Blank S , SeismannH, MichelY et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 66 , 1322–1329 (2011).
   PubMed Web of Science ®Google Scholar
• Ozdemir C , KucuksezerUC, AkdisM, AkdisCA. Mechanisms of immunotherapy to wasp and bee venom. Clin. Exp. Allergy41 , 1226–1234 (2011).
   PubMed Web of Science ®Google Scholar
• Jutel M , AkdisCA. T-cell regulatory mechanisms in specific immunotherapy. Chem. Immunol. Allergy94 , 158–171 (2008).
   PubMedGoogle Scholar
• Akdis CA , AkdisM, BleskenT et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98 , 1676–1683 (1996).
   PubMed Web of Science ®Google Scholar
• Bussmann C , XiaJ, AllamJP, MaintzL, BieberT, NovakN. Early markers for protective mechanisms during rush venom immunotherapy. Allergy65 , 1558–1565 (2010).
   PubMed Web of Science ®Google Scholar
• Jutel M , MüllerU, FrickerM, RihsS, PichlerWJ, DahindenC. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin. Exp. Allergy26 , 1112–1118 (1996).
   PubMed Web of Science ®Google Scholar
• Goldberg A , Confino-CohenR. Bee venom immunotherapy – how early is it effective? Allergy65 , 391–395 (2010).
   PubMedGoogle Scholar
• Bonifazi F , JutelM, BiloBM, BirnbaumJ, MullerU. EAACI Interest Group on insect venom hypersensitivity: prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy60 , 1459–1470 (2005).
   PubMed Web of Science ®Google Scholar
• Bilò BM , BonifaziF. Hymenoptera venom immunotherapy. Immunotherapy3 , 229–224 (2011).
   PubMed Web of Science ®Google Scholar
• Golden DB , MoffittJ, NicklasRA et al. Stinging insect hypersensitivity: a practice parameter update 2011. J. Allergy Clin. Immunol. 127 , 852–854, E1–E23 (2011).
   PubMed Web of Science ®Google Scholar
• Müller UR , JohansenN, PetersenAB, Fromberg-NielsenJ, HaeberliG. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy64 , 543–548 (2009).
   PubMed Web of Science ®Google Scholar
• Hofmann SC , PfenderN, WeckesserS, Huss-MarpJ, JakobT. Added value of IgE detection to rApi m 1 and rVes v 5 in patients with Hymenoptera venom allergy. J. Allergy Clin. Immunol.127 , 265–267 (2011).
   PubMed Web of Science ®Google Scholar
• Korošec P , ValentaR, MittermannI et al. Low sensitivity of commercially available rApi m1 for diagnosis of honeybee venom allergy. J. Allergy Clin. Immunol. 128 , 671–673 (2011).
   PubMed Web of Science ®Google Scholar
• Sturm GJ , HemmerW, HawranekT et al. Detection of IgE to recombinant Api m 1 and rVes v 5 is valuable but not sufficient to distinguish bee from wasp venom allergy. J. Allergy Clin. Immunol. 128 , 247–248 (2011).
   PubMed Web of Science ®Google Scholar
• Sturm GJ , BilóMB, BonadonnaP et al. Ves v 5 can establish the diagnosis in patients without detetable sIgE to wasp venom and a possible north–south difference in Api m1 sensitization in Europe. J. Allergy Clin. Immunol. 130(3) , 817 (2012).
   PubMed Web of Science ®Google Scholar
• Müller U , Schmid-GrendelmeierP, HausmannO, HelblingA. IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from cross reaction in venom allergy. Allergy67 , 1069–1073 (2012).
   PubMed Web of Science ®Google Scholar
• Jakob T , KöhlerJ, BlankS et al. Comparable IgE reactivity to natural and recombinant Api m1 in cross-reactive carbohydrate determinant-negative patients with bee venom allergy. J. Allergy Clin. Immunol. 130 , 276–278 (2012).
   PubMed Web of Science ®Google Scholar
• Mittermann I , ZidarnM, SilarM et al. Recombinant allergen-based IgE testing to distinguish bee and wasp allergy. J. Allergy Clin. Immunol. 125 , 1300–1307 (2010).
   PubMed Web of Science ®Google Scholar
• Mertens M , BrehlerR. Suitability of different glycoproteins and test systems for detecting cross-reactive carbohydrate determinant-specific IgE in hymenoptera venom-allergic patients. Int. Arch. Allergy Immunol.156 , 43–50 (2011).
   PubMed Web of Science ®Google Scholar
• Korosec P , ErzenR, SilarM, BajrovicN, KopacP, KosnikM. Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin. Exp. Allergy39 , 1730–1737 (2009).
   PubMed Web of Science ®Google Scholar
• Przybilla B , RuëffF. Hymenoptera venom allergy. J. Dtsch Dermatol. Ges.8 , 114–129 (2010).
   PubMed Web of Science ®Google Scholar
• Severino MG , CortelliniG, BonadonnaP et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 122 , 44–48 (2008).
   PubMed Web of Science ®Google Scholar
• Blaauw PJ , SmithuisLO. The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting. J. Allergy Clin. Immunol.75 , 556–562 (1985).
   PubMed Web of Science ®Google Scholar
• van der Linden PW , HackCE, StruyvenbergA, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J. Allergy Clin. Immunol.94 , 151– 159 (1994).
   PubMed Web of Science ®Google Scholar
• Ruëff F , PrzybillaB, BilóMB et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on insect venom hypersensitivity. J. Allergy Clin. Immunol. 124 , 047–054 (2009).
   Web of Science ®Google Scholar
• González-de-Olano D , Alvarez-TwoseI, VegaA, OrfaoA, EscribanoL. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy3 , 637–651 (2011).
   PubMed Web of Science ®Google Scholar
• Bonadonna P , PerbelliniO, PassalacquaG et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels. J. Allergy Clin. Immunol. 123 , 680–686 (2009).
   PubMed Web of Science ®Google Scholar
• Krishna MT , EwanPW, DiwakarL et al. British Society for Allergy and Clinical Immunology. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin. Exp. Allergy 41 , 1201–1220 (2011).
   PubMed Web of Science ®Google Scholar
• Müller UR . Cardiovascular disease and anaphylaxis. Curr. Opin Allergy Immunol.7 , 337–341 (2007).
   PubMed Web of Science ®Google Scholar
• Golden DB , KellyD, HamiltonRG, CraigTJ. Venom immunotherapy reduces large local reactions to insect stings. J. Allergy Clin. Immunol.123 , 1371–1375 (2009).
   PubMed Web of Science ®Google Scholar
• Muller U , HelblingA, BerchtoldE. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J. Allergy Clin. Immunol.89 , 529–535 (1992).
   PubMed Web of Science ®Google Scholar
• Ross RN , NelsonHS, FinegoldI. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin. Ther.22 , 351–358 (2000).
   PubMed Web of Science ®Google Scholar
• Watanabe AS , FonsecaLA, GalvaoCE, KalilJ, CastroFF. Specific immunotherapy using hymenoptera venom: systematic review. Sao Paulo Med. J.128 , 30–37 (2010).
   PubMed Web of Science ®Google Scholar
• Houliston L , NolanR, NobleV et al. Honeybee venom immunotherapy in children using a 50-mg maintenance dose. J. Allergy Clin. Immunol. 127 , 98–999 (2011).
   PubMed Web of Science ®Google Scholar
• Rueff F , WenderothA, PrzybillaB. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J. Allergy Clin. Immunol.108 , 1027–1032 (2001).
   PubMed Web of Science ®Google Scholar
• Goldberg A , YogevA, Confino-CohenR. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Int. Arch. Allergy Immunol.156 , 90–98 (2011).
   PubMed Web of Science ®Google Scholar
• Bilò MB , CintiB, BrianzoniMF, BraschiMC, BonifaziM, AntonicelliL. Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal basal serum tryptase concentrations. J. Allergy (Cairo). 2012 , 869243 (2012).
   Google Scholar
• Roumana A , PitsiosC, VartholomaiosS, KompotiE, Kontou-FiliK. The safety of initiating Hymenoptera immunotherapy at 1 µg of venom extract. J. Allergy Clin. Immunol.124 , 379–381 (2009).
   PubMed Web of Science ®Google Scholar
• Bilò MB , AntonicelliL, BonifaziF. Purified versus nonpurified venom immunotherapy. Curr. Opin Allergy Clin. Immunol.10 , 89330–89336 (2010).
   Google Scholar
• Cavallucci E , RamondoS, RenzettiA et al. Maintenance venom immunotherapy administered at a 3-month interval preserves safety and efficacy and improves adherence. J. Investig. Allergol. Clin. Immunol. 20 , 63–68 (2010).
   PubMed Web of Science ®Google Scholar
• Goldberg A , Confino-CohenR. Effectiveness of maintenance bee venom immunotherapy administered at 6-month intervals. Ann. Allergy Asthma Immunol.99 , 352–357 (2007).
   PubMed Web of Science ®Google Scholar
• Žitnik SE , VeselT, AvčinT, ŠilarM, KošnikM, KorošecP. Monitoring honeybee venom immunotherapy in children with the basophil activation test. Pediatr. Allergy Immunol.23 , 166–172 (2012).
   PubMedGoogle Scholar
• Incorvaia C , FratiF, Dell‘AlbaniI et al. Safety of hymenoptera venomimmunotherapy: a systematic review. Expert Opin Pharmacother. 12 , 2527–2532 (2011).
   PubMed Web of Science ®Google Scholar
• Ruëff F , PrzybillaB, BilóMB et al. European Academy of Allergy and Clinical Immunology Interest Group. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J. Allergy Clin. Immunol. 126 , 105–111 (2010).
   PubMed Web of Science ®Google Scholar
• Patella V , FlorioG, GiulianoA et al. Hymenoptera venom immunotherapy: tolerance and efficacy of an ultrarush protocol versus a rush and a slow conventional protocol. J. Allergy (Cairo) 2012 , 192192 (2012).
   Google Scholar
• Kalogeromitros D , MakrisM, KotiI et al. A simple 3-day “rush” venom immunotherapy protocol: documentation of safety. Allergol. Immunopathol. 38 , 69–73 (2010).
   PubMed Web of Science ®Google Scholar
• Müller UR , HaeberliG. Use of β-blockers during immunotherapy for Hymenoptera venom allergy. J. Allergy Clin. Immunol.115 , 606–610 (2005).
   PubMed Web of Science ®Google Scholar
• Müller U , HariY, BerchtoldE. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J. Allergy Clin. Immunol.107 , 81–86 (2001).
   PubMed Web of Science ®Google Scholar
• Müller UR , JutelM, ReimersA et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J. Allergy Clin. Immunol. 122 , 1001–1007 (2008).
   PubMed Web of Science ®Google Scholar
• Galera C , SoohunN, ZankarN, CaimmiS, GallenC, DemolyP. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J. Investig. Allergol. Clin. Immunol.19 , 225–229 (2009).
   PubMed Web of Science ®Google Scholar
• Gomis VS , DelgadoPG, HernandezEN. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J. Investig. Allergol. Clin. Immunol.18 , 225–226 (2008).
   PubMed Web of Science ®Google Scholar
• Rueff F , BiloMB, JutelM, MosbechH, MullerU, PrzybillaB. Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy. J. Allergy Clin. Immunol.123 , 272–273 (2009).
   PubMed Web of Science ®Google Scholar
• Ruëff F , WolfH, SchnitkerJ et al. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 59 , 589–595 (2004).
   PubMed Web of Science ®Google Scholar
• Bilò MB , SeverinoM, CiliaM et al. The VISYT trial: venom immunotherapy safety and tolerability with purified vs nonpurified extracts. Ann. Allergy Asthma Immunol. 103 , 57–61 (2009).
   PubMed Web of Science ®Google Scholar
• Muller U , BerchtoldE, HelblingA. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J. Allergy Clin. Immunol.87 , 702 (1991).
   PubMed Web of Science ®Google Scholar
• Lerch E , MullerUR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J. Allergy Clin. Immunol.101 , 606–612 (1998).
   PubMed Web of Science ®Google Scholar
• Golden DB . Long-term outcome after venom immunotherapy. Curr. Opin Allergy Clin. Immunol.10 , 337–341 (2010).
   PubMed Web of Science ®Google Scholar
• Hockenhull J , ElremeliM, CherryMG et al. A systematic review of the clinical effectiveness and cost effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. Health Technol. Assess. 16 , III–IV, 1–110 (2012).
   PubMed Web of Science ®Google Scholar
• Münstedt K , WrobelD, KalderM. Efficacy of venom immunotherapy in beekeepers. J. Investig. Allergol. Clin. Immunol.20 , 58–62 (2010).
   PubMed Web of Science ®Google Scholar
• Müller UR . Recent developments and future strategies for immunotherapy of insect venom allergy. Curr. Opin Allergy Clin. Immunol.3 , 299–303 (2003).
   PubMed Web of Science ®Google Scholar
• Fellrath JM , KettnerA, DufourN et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J. Allergy Clin. Immunol. 111 , 854–861 (2003).
   PubMed Web of Science ®Google Scholar
• Jilek S , BarbeyC, SpertiniF, CorthesyB. Antigen independent suppression of the allergic immune response to bee venom phospholipase A2 by DNA vaccination in CBA/J mice. Immunology166 , 3612–3621 (2001).
   Web of Science ®Google Scholar
• Kussebi F , KaramlooF, RhynerC et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol. 115 , 323–329 (2005).
   PubMed Web of Science ®Google Scholar
• Karamloo F , Schmid-GrendelmeierP, KussebiF et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur. J. Immunol. 35 , 3268–3276 (2005).
   PubMed Web of Science ®Google Scholar
• Müller UR , AkdisCA, FrickerM et al. Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J. Allergy Clin. Immunol. 101 , 747–754 (1998).
   PubMed Web of Science ®Google Scholar
• Senti G , Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl Acad. Sci. USA105 , 17908–17912 (2008).
   PubMed Web of Science ®Google Scholar
• Senti G , JohansenP, KündigTM. Intralymphatic immunotherapy. Curr. Opin Allergy Clin. Immunol.9 , 537–543 (2009).
   PubMed Web of Science ®Google Scholar

▪ Website

• IUIS Allergen Nomenclature Sub-Committee. www.allergen.org
   Google Scholar